Equivocal Findings of Alzheimer’s Trial Using Young Blood
A team of Stanford University researchers say that administering young people’s blood plasma to Alzheimer’s patients could improve cognitive function, but the results have been criticized.
November 6, 2017|
“The scientific basis for the trial is simply not there,” Irina Conboy, a neurologist at the University of California, Berkeley, tells Nature. “The effects of young blood on cognition have not been replicated by an independent group, and there has never been a test with a mouse model of Alzheimer’s.”
The current trial’s rationale comes from work in the lab of Stanford’s Tony Wyss-Coray, who had previously shown that young mouse blood could improve physical and cognitive function in older mice. The California-based startup Alkahest, founded in 2014 by Wyss-Coray, gained approval to test the approach in Alzheimer’s patients a couple years ago.
But the trial itself, initially designed to be placebo-controlled, did not go according to plan. To begin with, nine patients with mild to moderate Alzheimer’s received weekly infusions for four weeks of either saline or plasma from male donors between 18 and 30 years old. After several people dropped out, however, a new trial was started in which there was no placebo group, just weekly injections of plasma.
Michael Conboy—also at the University of California, Berkeley—tells New Scientist that this design could make the results of the trial unusable. “It’s like picking all the aces out of a deck of cards and then shuffling the deck,” he says.
On cognitive tests administered by the researchers, Alzheimer’s patients receiving plasma injections did no better than expected. But the researchers reported that caregivers answering questionnaires reported slight improvements in their patients’ performance of daily tasks. Significantly, it was the patients in the first trial, who did not know whether they were receiving plasma or saline, who showed the most improvement by this measure after plasma injections, the study’s principal investigator, Sharon Sha, says in a statement.
Alkahest has already announced plans to move forward the clinical development of plasma-based treatment for mild to moderate Alzheimer’s disease.
For now, though, it’s unclear how the treatment might work—a concern raised by several researchers who were not involved in the study. “They need to explain the potential mode of action,” Zaven Khachaturian, a neuroscientist recently retired from the National Institute on Aging in Bethesda, Maryland, tells Science. “[Patients] could feel better because somebody paid attention to them.”